Compare Stocks

→ You’re invited: Biggest crypto event of 2024 (From InvestorPlace) (Ad)

Compare stocks and their fundamentals, performance, price, and technicals. Use this free stock comparison tool to evaluate companies based on their analyst ratings, book value, debt, dividend, MarketRank, news sentiment, price performance, profitability, and more. Enter up to ten stock symbols separated by a comma or space (ex. BAC, JPM, WFC, C, GS).

Comparative Price Performance Over Time

Compare Stocks - Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ABIO ARCA biopharma	$3.25 +1.2%	$2.04	$1.56 ▼ $3.88	$47.13M	1.17	1.18 million shs	218,431 shs
ATHE Alterity Therapeutics	$2.14 +6.5%	$1.93	$1.55 ▼ $5.41	$9.99M	0.94	78,332 shs	25,391 shs

Elon Musk's Next Move

Wondering when you'll finally be able to invest in SpaceX, StarLink, or The Boring Company? Click the link below to learn when Elon Musk will let these companies finally IPO.

Get This Free Report

Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ABIO ARCA biopharma	+1.25%	0.00%	+86.78%	+103.13%	+64.14%
ATHE Alterity Therapeutics	+3.38%	-18.63%	+28.14%	+15.05%	-26.46%

Forget Bitcoin. Crypto Millionaire Predicts 8,788% Gains For THIS (Ad)

You might have seen that Bitcoin was one of the best performing assets of 2023. It gained 164%. But a crypto millionaire who has been tracking the space for more than a decade has ABANDONED Bitcoin. He found something better.

Click here to find out that this 8,788% cryptocurrency is.

MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	3.6372 of 5 stars	3.5	5.0	0.0	0.0	4.2	1.7	1.3

Analyst Ratings

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ABIO ARCA biopharma	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	3.00	Buy	$7.00	227.10% Upside

Current Analyst Ratings

Latest ATHE and ABIO Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target	Details
3/7/2024	ATHE Alterity Therapeutics	Benchmark Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Speculative Buy ➝ Speculative Buy	$4.00

(Data available from 4/19/2021 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	$2.89 per share	N/A
ATHE Alterity Therapeutics	$3.37M	2.97	N/A	N/A	$3.78 per share	0.57

Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ABIO ARCA biopharma	-$5.34M	-$0.37	N/A	∞	N/A	N/A	-13.80%	-13.33%	4/22/2024 (Estimated)
ATHE Alterity Therapeutics	-$9.30M	N/A	0.00	N/A	N/A	N/A	N/A	N/A	N/A

Latest ATHE and ABIO Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue	Details
2/1/2024	Q4 2023	ABIO ARCA biopharma	N/A	-$0.08	-$0.08	-$0.08	N/A	N/A

Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ABIO ARCA biopharma	N/A	N/A	N/A	N/A	N/A
ATHE Alterity Therapeutics	N/A	N/A	N/A	N/A	N/A

Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ABIO ARCA biopharma	N/A	59.01	59.01
ATHE Alterity Therapeutics	N/A	4.89	N/A

Ownership

Institutional Ownership

Company	Institutional Ownership
ABIO ARCA biopharma	56.44%
ATHE Alterity Therapeutics	2.14%

Insider Ownership

Company	Insider Ownership
ABIO ARCA biopharma	30.90%
ATHE Alterity Therapeutics	38.80%

Miscellaneous

Company	Employees	Shares Outstanding	Free Float	Optionable
ABIO ARCA biopharma	4	14.50 million	10.02 million	Optionable
ATHE Alterity Therapeutics	11	4.67 million	2.86 million	Not Optionable

ATHE and ABIO Headlines

Source	Headline
	Alterity Therapeutics Parkinson’s Disease and Multiple System Atrophy Data Featured at the American Academy of Neurology (AAN) 2024 Annual Meeting finance.yahoo.com - April 17 at 8:21 AM
	Alterity Therapeutics to Present New Data on ATH434 at the World Orphan Drug Congress USA 2024 globenewswire.com - April 10 at 7:25 AM
	Critical Analysis: Alterity Therapeutics (NASDAQ:ATHE) vs. Antibe Therapeutics (OTCMKTS:ATBPF) americanbankingnews.com - April 10 at 1:18 AM
	Alterity Therapeutics Limited (ATHE) finance.yahoo.com - April 5 at 12:19 PM
	Alterity Therapeutics Receives a A$3.9 Million Research & Development Tax Incentive Refund globenewswire.com - March 26 at 10:25 AM
	Alterity Therapeutics Ltd ADR ATHE morningstar.com - March 24 at 11:05 PM
	ATHE Alterity Therapeutics Limited seekingalpha.com - March 22 at 9:44 PM
	Alterity Therapeutics Ltd. ADR wsj.com - March 22 at 9:44 PM
	Alterity Therapeutics drops on capital raise msn.com - February 23 at 1:58 PM
	Alterity Therapeutics Stock (NASDAQ:ATHE), Short Interest Report benzinga.com - February 22 at 7:35 AM
	Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting finance.yahoo.com - February 20 at 4:16 PM
	Alterity Therapeutics to Present New Data at the Upcoming American Academy of Neurology 2024 Annual Meeting globenewswire.com - February 20 at 10:25 AM
	Alterity Therapeutics to Participate in the ShareCafe Hidden Gems Webinar This Week finance.yahoo.com - January 29 at 10:07 AM
	Alterity Therapeutics Issues Shareholder Letter Highlighting Pipeline Advances and Key Upcoming Milestones finance.yahoo.com - January 22 at 9:05 AM
	ALTERITY THERAPEUTICS LIMITED: Alterity Therapeutics Appoints Phillip Hains as Chief Financial Officer finanznachrichten.de - December 21 at 10:07 AM
	Alterity Therapeutics to Host Webcast to Discuss ATH434 Efficacy Data in Primates and Recent Clinical Progress finance.yahoo.com - December 4 at 7:16 PM
	Alterity Therapeutics Shares Up Fivefold on New Parkinson's Drug Data marketwatch.com - December 4 at 2:16 PM
	Why Is Neurodegenerative Disease-Focused Alterity Therapeutics Stock Trading Over 200% Higher Today? msn.com - December 4 at 2:16 PM
	Biotech Alterity Jumps On Upbeat Parkinson's Treatment Clinical Trial Data finance.yahoo.com - December 4 at 2:16 PM
	Alterity Therapeutics Reports Positive Efficacy Data for ATH434 in a Primate Model of Parkinson’s Disease finance.yahoo.com - December 4 at 8:15 AM
	Alterity Therapeutics Announces Presentation of Novel Biomarker Data for Evaluation of Multiple System Atrophy finance.yahoo.com - November 27 at 8:57 AM
	Alterity Therapeutics Limited's (ASX:ATH) CEO Compensation Is Looking A Bit Stretched At The Moment finance.yahoo.com - November 22 at 8:08 PM
	Alterity Therapeutics, Edesa Biotech among healthcare movers msn.com - November 22 at 3:07 PM
	Alterity Therapeutics ADRs Shares Dive 31% on Raised Capital marketwatch.com - November 22 at 3:07 PM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Company Descriptions

ARCA biopharma

NASDAQ:ABIO

ARCA biopharma, Inc., a clinical stage biopharmaceutical company, engages in the development and commercialization of targeted therapies for cardiovascular diseases. Its lead product candidate is Gencaro, a pharmacogenetically-targeted beta-adrenergic receptor antagonist that has completed Phase IIb trial for the treatment of atrial fibrillation in patients with heart failure. It is developing Recombinant Nematode Anticoagulant Protein c2, a protein therapeutic that is in Phase IIb clinical trial for the treatment for COVID-19. The company has a collaboration agreement with LabCorp to develop genetic test for GENETIC-AF clinical trial. ARCA biopharma, Inc. is headquartered in Westminster, Colorado.

Alterity Therapeutics

NASDAQ:ATHE

Alterity Therapeutics Limited engages in the research and development of therapeutic drugs to treat Alzheimer's disease, Huntington disease, Parkinson's disease, and other neurological disorders in Australia. The company's lead drug candidate is ATH434 that is in Phase I clinical trial for the treatment of Parkinson's disease. It is also developing ATH434-201, which is in Phase II clinical trial to treat multiple system atrophy early stage; ATH434-202 that is in Phase II clinical trial to treat multiple system atrophy advance; and PBT2 that has completed Phase 2a clinical trial to treat Alzheimer's disease. The company was formerly known as Prana Biotechnology Limited and changed its name to Alterity Therapeutics Limited in April 2019. Alterity Therapeutics Limited was incorporated in 1997 and is headquartered in Melbourne, Australia.

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial